See more : SI-BONE, Inc. (SIBN) Income Statement Analysis – Financial Results
Complete financial analysis of PURE Bioscience, Inc. (PURE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PURE Bioscience, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.
You may be interested
- Amala Foods Plc (DISH.L) Income Statement Analysis – Financial Results
- H S India Limited (HOTLSILV.BO) Income Statement Analysis – Financial Results
- National Lampoon Inc. (NLMP) Income Statement Analysis – Financial Results
- PT Indointernet Tbk. (EDGE.JK) Income Statement Analysis – Financial Results
- CFM Indosuez Wealth Management SA (MLCFM.PA) Income Statement Analysis – Financial Results
PURE Bioscience, Inc. (PURE)
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.96M | 1.88M | 1.85M | 3.93M | 6.92M | 1.91M | 1.77M | 1.83M | 1.29M | 729.00K | 550.00K | 820.00K | 812.00K | 464.18K | 1.44M | 728.26K | 1.49M | 336.39K | 200.43K | 155.81K | 263.50K | 2.59M | 3.21M | 2.41M | 1.66M | 3.40M | 1.70M | 1.00M | 800.00K |
| Cost of Revenue | 811.00K | 906.00K | 853.00K | 1.85M | 2.90M | 728.00K | 763.00K | 760.00K | 441.00K | 285.00K | 344.00K | 565.00K | 264.00K | 131.39K | 465.09K | 238.17K | 463.60K | 221.11K | 105.72K | 51.59K | 130.90K | 1.53M | 1.60M | 1.36M | 885.25K | 1.30M | 900.00K | 600.00K | 600.00K |
| Gross Profit | 1.15M | 971.00K | 1.00M | 2.08M | 4.02M | 1.18M | 1.01M | 1.07M | 848.00K | 444.00K | 206.00K | 255.00K | 548.00K | 332.79K | 971.04K | 490.10K | 1.02M | 115.28K | 94.71K | 104.21K | 132.60K | 1.06M | 1.61M | 1.05M | 776.21K | 2.10M | 800.00K | 400.00K | 200.00K |
| Gross Profit Ratio | 58.69% | 51.73% | 53.97% | 52.84% | 58.13% | 61.86% | 56.99% | 58.49% | 65.79% | 60.91% | 37.45% | 31.10% | 67.49% | 71.69% | 67.61% | 67.30% | 68.83% | 34.27% | 47.25% | 66.89% | 50.32% | 40.76% | 50.15% | 43.45% | 46.72% | 61.76% | 47.06% | 40.00% | 25.00% |
| Research & Development | 302.00K | 297.00K | 319.00K | 339.00K | 322.00K | 354.00K | 459.00K | 779.00K | 927.00K | 790.00K | 1.03M | 1.33M | 1.86M | 2.18M | 1.93M | 1.47M | 1.65M | 1.22M | 1.19M | 1.36M | 1.13M | 981.49K | 780.51K | 292.96K | 114.76K | 200.00K | 200.00K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 4.05M | 0.00 | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 4.93M | 5.46M | 5.14M | 3.74M | 2.61M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 927.94K | 694.07K | 805.63K | 899.15K | 570.16K | 427.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.98M | 4.30M | 4.11M | 4.05M | 3.70M | 6.42M | 7.59M | 6.30M | 6.98M | 7.29M | 8.32M | 5.72M | 7.44M | 6.52M | 5.86M | 6.16M | 5.95M | 3.74M | 2.61M | 1.76M | 1.63M | 3.28M | 2.77M | 2.57M | 2.31M | 1.50M | 2.40M | 1.90M | 700.00K |
| Other Expenses | 0.00 | -4.00K | 0.00 | -4.00K | 5.00K | 1.00K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 109.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 277.83K | 0.00 | 212.17K | 100.00K | 100.00K | 100.00K | 0.00 |
| Operating Expenses | 4.28M | 4.60M | 4.43M | 4.39M | 4.02M | 6.77M | 8.05M | 7.08M | 7.91M | 8.08M | 9.35M | 7.04M | 9.30M | 8.70M | 7.79M | 7.62M | 7.70M | 4.96M | 3.81M | 3.12M | 2.76M | 4.27M | 3.83M | 2.87M | 2.64M | 1.80M | 2.70M | 2.00M | 700.00K |
| Cost & Expenses | 5.09M | 5.51M | 5.28M | 6.24M | 6.91M | 7.50M | 8.82M | 7.84M | 8.35M | 8.37M | 9.70M | 7.61M | 9.57M | 8.83M | 8.25M | 7.86M | 8.17M | 5.18M | 3.91M | 3.17M | 2.89M | 5.80M | 5.43M | 4.23M | 3.52M | 3.10M | 3.60M | 2.60M | 1.30M |
| Interest Income | 0.00 | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 7.77K | 33.31K | 18.72K | 30.79K | 150.88K | 0.00 | 0.00 | 191.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 155.00K | 14.00K | 6.00K | 4.00K | 5.00K | 6.00K | 8.00K | 5.00K | 10.00K | 8.00K | 10.00K | 0.00 | 145.00K | -232.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 315.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 148.00K | 117.00K | 213.00K | 172.00K | 192.00K | 241.00K | 285.00K | 276.00K | 219.00K | 185.00K | 2.14M | 601.00K | 377.00K | 460.60K | 442.05K | 396.47K | 403.38K | 219.59K | 310.90K | 305.53K | 348.72K | 314.08K | 734.63K | 290.44K | 252.37K | 100.00K | 100.00K | -100.00K | 0.00 |
| EBITDA | -3.05M | -3.83M | -3.27M | -2.14M | 201.00K | -6.31M | -7.15M | -5.99M | -14.14M | -7.43M | -8.90M | -6.48M | -8.36M | -7.91M | -6.29M | -6.74M | -6.28M | -4.62M | -3.46M | -2.74M | -2.35M | -3.25M | -1.49M | -1.32M | -1.61M | 400.00K | -1.80M | -1.70M | -500.00K |
| EBITDA Ratio | -155.22% | -187.27% | -173.34% | -54.57% | 2.91% | -280.09% | -379.48% | -299.40% | 36.15% | -1,022.63% | -1,274.18% | -754.51% | -1,031.65% | -1,703.28% | -443.97% | -925.21% | -421.99% | -1,373.77% | -1,697.21% | -1,736.55% | -864.41% | -111.82% | -46.32% | -63.40% | -96.71% | 11.76% | -105.88% | -170.00% | -62.50% |
| Operating Income | -3.13M | -3.94M | -3.43M | -2.31M | 9.00K | -5.59M | -7.04M | -6.01M | 247.00K | -7.64M | -9.15M | -6.79M | -8.75M | -8.37M | -6.82M | -7.13M | -6.68M | -4.84M | -3.71M | -3.01M | -2.63M | -3.21M | -2.22M | -1.82M | -1.86M | 300.00K | -1.90M | -1.60M | -500.00K |
| Operating Income Ratio | -159.50% | -210.07% | -184.84% | -58.85% | 0.13% | -292.77% | -396.96% | -328.13% | 19.16% | -1,048.01% | -1,663.27% | -827.80% | -1,078.08% | -1,802.51% | -474.75% | -979.65% | -449.11% | -1,439.05% | -1,852.32% | -1,932.65% | -996.75% | -123.95% | -69.24% | -75.45% | -111.90% | 8.82% | -111.76% | -160.00% | -62.50% |
| Total Other Income/Expenses | -219.00K | -18.00K | 233.00K | -8.00K | 0.00 | -965.00K | -400.00K | -255.00K | -7.31M | 13.00K | 852.00K | -332.00K | -136.00K | 17.77K | 60.35K | 69.53K | 142.44K | 188.37K | 32.12K | -638.00 | -194.43K | 402.98K | -280.23K | -167.58K | 34.67K | 0.00 | 0.00 | 200.00K | 0.00 |
| Income Before Tax | -3.35M | -3.96M | -3.49M | -2.32M | 4.00K | -6.55M | -7.44M | -6.26M | -14.37M | -7.63M | -11.05M | -7.67M | -8.75M | -8.36M | -6.76M | -7.06M | -6.54M | -4.65M | -3.68M | -3.01M | -2.70M | -3.19M | -2.50M | -1.78M | -1.82M | 0.00 | 0.00 | -1.40M | 0.00 |
| Income Before Tax Ratio | -170.66% | -211.03% | -188.40% | -59.05% | 0.06% | -343.32% | -419.50% | -342.05% | -1,114.90% | -1,046.23% | -2,009.09% | -935.49% | -1,077.09% | -1,800.35% | -470.55% | -970.11% | -439.53% | -1,383.05% | -1,836.30% | -1,933.06% | -1,024.56% | -123.06% | -77.98% | -73.89% | -109.81% | 0.00% | 0.00% | -140.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.00K | 6.00K | -68.56K | 10.00K | 7.00K | 33.00K | 255.00K | 7.31M | -13.00K | 1.90M | 883.00K | 136.00K | -17.77K | 2.52K | 2.40K | 2.40K | 2.40K | 132.39K | -1.16M | -318.77K | 74.35K | 224.88K | 1.60K | 800.00 | 0.00 | 0.00 | -200.00K | -100.00K |
| Net Income | -3.35M | -3.96M | -3.50M | -2.32M | -6.00K | -6.56M | -7.48M | -6.52M | -21.69M | -7.61M | -12.95M | -8.55M | -8.88M | -8.34M | -6.76M | -7.07M | -6.54M | -4.65M | -3.81M | -1.85M | -2.38M | -3.26M | -2.73M | -1.78M | -1.83M | 300.00K | -1.90M | -1.20M | -400.00K |
| Net Income Ratio | -170.66% | -211.03% | -188.72% | -59.05% | -0.09% | -343.69% | -421.36% | -355.98% | -1,682.31% | -1,044.44% | -2,354.91% | -1,043.17% | -1,093.84% | -1,796.53% | -470.73% | -970.43% | -439.70% | -1,383.77% | -1,902.35% | -1,185.53% | -903.58% | -125.93% | -84.99% | -73.96% | -109.86% | 8.82% | -111.76% | -120.00% | -50.00% |
| EPS | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -3.01 | 0.47 | -3.92 | -2.88 | -1.12 |
| EPS Diluted | -0.03 | -0.04 | -0.04 | -0.03 | 0.00 | -0.09 | -0.11 | -0.10 | -0.38 | -0.19 | -0.51 | -0.79 | -1.58 | -1.79 | -1.57 | -1.85 | -1.90 | -1.52 | -1.49 | -0.92 | -1.55 | -2.86 | -2.85 | -2.24 | -1.81 | 0.31 | -3.92 | -2.88 | -1.12 |
| Weighted Avg Shares Out | 111.86M | 111.40M | 88.84M | 87.17M | 82.21M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 605.61K | 637.50K | 484.69K | 416.67K | 357.14K |
| Weighted Avg Shares Out (Dil) | 111.86M | 111.40M | 88.84M | 87.17M | 84.61M | 72.88M | 67.28M | 63.49M | 56.83M | 39.75M | 25.61M | 10.84M | 5.62M | 4.67M | 4.32M | 3.82M | 3.44M | 3.06M | 2.56M | 2.01M | 1.53M | 1.14M | 955.04K | 795.64K | 1.01M | 637.50K | 484.69K | 416.67K | 357.14K |
PURE Bioscience Reports Fiscal Second Quarter 2024 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2024. Summary of Results –...
PURE Bioscience Reports Fiscal First Quarter 2024 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2023. Summary of Results –...
PURE Bioscience Reports Fiscal 2023 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023. Summary of Results – Year-End...
PURE Bioscience Reports Fiscal 2021 Third Quarter and Nine-Month Financial Results
RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) (the “Company,” “PURE” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter and nine-month period ended April 30, 2021. Q3:...
MACOM Introduces New GaN-on-Silicon Carbide (SiC) Power Amplifier Product Line MACOM PURE CARBIDETM
MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor solutions, today announced at the virtual International Microwave Sympo
PURE Bioscience Sets Fiscal 2019 Third Quarter and Nine-Month Financial Results Call
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2019 the Company will file its Form 10-Q shortly after the close of the market and will...
PURE Bioscience Sets Fiscal 2019 Second Quarter and Six-Month Financial Results Call
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on March 6, 2019 the Company will file its Form 10-Q shortly after the close of the market and will...
PURE Bioscience Sets Fiscal 2019 Q1 Financial Results Conference Call
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on December 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will...
PURE Bioscience Sets Conference Call to Report 2018 Fiscal Year-End Financial Results
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on October 25, 2018 the Company will file its Form 10-K shortly after the close of the market and will...
PURE Bioscience Sets Conference Call to Report 2018 Fiscal Third Quarter and Nine-Month Financial Results
SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial, announced today that on June 13, 2018 the Company will file its Form 10-Q shortly after the close of the market and will...
Source: https://incomestatements.info
Category: Stock Reports